{"id":15627,"date":"2021-11-04T15:11:23","date_gmt":"2021-11-04T15:11:23","guid":{"rendered":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/?p=15627"},"modified":"2021-11-09T19:43:10","modified_gmt":"2021-11-09T19:43:10","slug":"preemptive-pgx-at-the-population-scale-implementation-in-pittsburgh","status":"publish","type":"post","link":"https:\/\/www.thermofisher.com\/blog\/behindthebench\/preemptive-pgx-at-the-population-scale-implementation-in-pittsburgh\/","title":{"rendered":"Preemptive PGx at the Population Scale: Implementation in Pittsburgh"},"content":{"rendered":"

\"A<\/p>\n

Determining the clinical utility of pharmacogenomics (PGx)<\/a> at a population level was a key driver for the University of Pittsburgh (Pitt) and Thermo Fisher Scientific to collaborate in the development and launch of a PGx Center of Excellence in School of Pharmacy.1<\/sup> The collaboration paired the expansive Pitt\/University of Pittsburgh Medical Center\u2019s (UPMC) health system, the largest academic health system in the U.S.,1<\/sup> with Thermo Fisher\u2019s comprehensive genetic testing solutions and implementation services.<\/p>\n

\u201cIn a Partnership with Thermo Fisher, which [is] certainly a leading innovator in developing testing solutions, we brought this new center of excellence to Pittsburgh with the goal of doing pre-emptive panel-based testing in >150,000 patients and be able to return these results to researchers and clinicians.\u201d<\/em><\/p>\n

In this enlightening session<\/a>, Dr. Philip Empey recounts the story of the PGx Center of Excellence, from concept to collaboration. Dr. Empey shares the teams\u2019 initial goals and strategies to establish the population-scale testing program and the ongoing measures at UPMC to deliver superior, cost-effective patient care and to advance understanding of genetic variation effects on medication response.<\/p>\n